Cited by 215Breast Cancer Treatment StudiesBreast Lesions and CarcinomasS100 Proteins and Annexins

Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer

Bauer, Maret, Eickhoff, Jens C., Gould, Michael N., Mundhenke, Christoph, Maass, Nicolai, Friedl, Andreas·2008·Breast Cancer Research and Treatment

Abstract

Neutrophil gelatinase-associated lipocalin (NGAL) is a small, secreted glycoprotein with proposed functions in cell proliferation, survival and morphogenesis. NGAL is expressed in a variety of tumor types including breast carcinomas, but it is not known whether NGAL contributes directly to breast cancer progression. This study examines the relationship between NGAL expression in breast carcinomas and established clinical prognostic markers as well as clinical outcome. Using immunohistochemistry in tissue microarrays containing well characterized tumor samples from 207 breast cancer patients, NGAL was detected in 68 breast carcinomas in a cytoplasmic location. NGAL expression correlated strongly with negative steroid receptor status, HER-2/neu overexpression, poor histologic grade, the presence of lymph node metastases and a high Ki-67 proliferation index. In univariate survival analysis, NGAL expression was associated with decreased disease-specific survival and decreased disease-free survival in the entire cohort. In multivariate analysis, NGAL remained an independent prognostic marker for disease-free survival. In a subset of patients with estrogen receptor positive tumors, NGAL was significantly associated with decreased disease-free survival. The results show that NGAL expression is a predictor of poor prognosis in primary human breast cancer and suggest that NGAL detection may provide information for risk assessment and identify a subset of patients requiring more aggressive adjuvant therapy.

Integrity signals

Registry

Crossref · 10.1007/s10549-007-9619-3

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bauer, M., Eickhoff, J. C., Gould, M. N., Mundhenke, C., Maass, N., & Friedl, A.
Affiliations
  • University of Wisconsin–Madison (US)
  • University Hospital Schleswig-Holstein (DE)
Corresponding author
Friedl, Andreas
Venue
Breast Cancer Research and Treatment
Published
2007-06-07
Volume
108
Issue
3
Pages
389-397
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
OpenAlex
W1967535690
Cited by
215
References
41
Citations by year
2026: 1 · 2025: 4 · 2024: 10 · 2023: 8 · 2022: 7 · 2021: 12 · 2020: 5 · 2019: 12 · 2018: 8 · 2017: 9 · 2016: 9 · 2015: 11 · 2014: 17 · 2013: 16 · 2012: 29
FWCI
4.35
Type
journal article
Language
en
Open access
closed
Locations
  • Breast Cancer Research and Treatment (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Deutsche Krebshilfe
  • National Institutes of Health
  • National Cancer Institute (R01CA107012)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › S100 Proteins and Annexins
Keywords
neutrophil gelatinase-associated lipocalin, breast cancer, prognostic factors, disease-free survival, disease-specific survival, estrogen receptor status, HER-2/neu overexpression, Ki-67 proliferation index, lymph node metastasis, histologic grade, adjuvant therapy
MeSH terms
Lipocalin-2, Acute-Phase Proteins, Breast Neoplasms, Female, Humans, Immunohistochemistry, Middle Aged, Prognosis, Proto-Oncogene Proteins, Biomarkers, Tumor, Disease-Free Survival, Tissue Array Analysis, Kaplan-Meier Estimate, Lipocalins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review